Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-04-24
2010-06-08
Horlick, Kenneth R. (Department: 1637)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200
Reexamination Certificate
active
07732141
ABSTRACT:
The methods of the invention detect in a qualitative or quantitative fashion drug-resistance RNA and DNA in blood plasma, serum, and other bodily fluids. The methods of the invention thereby enable the assessment of drug resistance in a neoplasm without the requirement of a tissue biopsy. The inventive methods are useful for the evaluation, monitoring, and selecting of drug treatment regimens, and for determining a predisposition for or prognosis of chemoresistant neoplastic disease.
REFERENCES:
patent: 5665549 (1997-09-01), Pinkel
patent: 6159685 (2000-12-01), Pinkel
patent: 6329179 (2001-12-01), Kopreski
patent: 6335167 (2002-01-01), Pinkel
patent: 3717212 (1988-12-01), None
patent: 90/09456 (1990-08-01), None
patent: 97/35589 (1997-10-01), None
patent: 98/14617 (1998-04-01), None
Hinds et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Research (1991) vol. 51, pp. 4729-4731.
Kopreski et al. “Detection of Tumor Messenger RNA in the Serum of Patients with Malignant Melanoma,” (1999), Clinical Cancer Research 5: 1961-1965.
Leitzel et al. “Detection of Cancer Cells in Peripheral Blood of Breast Cancer Patients Using Reverse Transcription-Polymerase Chain Reaction for Epidermal Growth Factor Receptor,” (1998), Clinical Cancer Research 4: 3037-3043.
Tamamiyagi et al. “Quantitative analysis of ferrochelatase mRNA in blood cells of erythropoietic protoporphyria,” (1996), Journal of Dermatological Science 11(2): 154-160.
Garbarz et al. “Spectrin B, a Novel Shortened B-Chain Variant Associated with Hereditary Elliptocytosis is Due to a Deletional Frameshift Mutation in the B-Spectrin Gene,” (1992), Blood 80(4): 1066-1073.
Monteyne et al. “Expression of costimulatory molecules and cytokines and in CSF and peripheral blood mononuclear cells from multiple sclerosis patients,” (1999), Acta Neurological Belgica 1(99): 11-20.
Serra et al. “Multiple sclerosis and multiple sclerosis-associated retrovirus in Sardinia,” (2001), Neurological Sciences 22(2): 171-173.
Kopreski et al. “Comparing Utility in DNA and RNA Molecular Marker Assessment,” (2000), Annals of New York Academy of Sciences 906: 124-128.
Messner et al. “Expression of Messenger RNA of the Cardiac Isoforms of Troponin T and I in Mysopathic Skeletal Muscle,” (2000), American Journal of Clinical Pathology 114(4): 544-549.
Kamm et al. “Nucleic Acid Concentrations in Normal Human Plasma,” (1972), Clinical Chemistry 18(6): 519-522.
Shutack et al. “A study of the RNA levels of normal blood serum,” (1968), Journal of the American Osteopathic Association 67(9): 1051-1053.
Guin et al. “Electrophoretic Characterization of Plasma RNA,” (1975), Biochemical Medicine 13(3): 224-230.
Stroun et al. “Presence of RNA in the Nucleoprotein Complex Spontaneously Released by Human Lymphocytes and Frog Auricles in Culture,” (1978), Cancer Res. 38(10): 3546-3554.
Allouche et al. “Expression of Basic Fibroblast Growth Factor (bFGF) and FGF-Receptors in Human Leukemic Cells,” (1995), Leukemia 9(1): 77-86.
Ricchiuti et al. “Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling,” (1997), Clin. Chem. 43(6): 990-995.
Ricchiuti et al. “Expression of cardiac troponin T mRNA in Skeletal muscle from patients with end stage renal disease and muscular dystrophy,” (1999), Clin. Chem. 45(6): A144-A145.
Ricchiuti et al. “RNA Expression of Cardiac Troponin T Isoforms in Diseased Human Skeletal Muscle,” (1999), Clin. Chem. 45(12): 2129-2135.
Rosenzweig et al. “Preclinical Diagnosis of Familial Hypertrophic Cardiomyopathy by Genetic Analysis of Blood Lymphocytes,” (1981), New England Journal of Medicine 325(25): 1753-1760.
Spiegelman et al. “The Development and Use of Extracelluar RNA Replication System,” (1969), The Harvey Lectures No. 64, pp. 1-67.
Komeda et al. “Sensitiv Detection of Circulating Hepatocellular Carcinoma Cells in Peripheral Venous Blood,” (1995), Cancer 75: 2214-2219.
Hasselmann et al. “Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma,” (2001), Oncol. Rep. 8: 115-118.
Chen et al. “Telomerase RNA as a Detection Marker in the Serum of Breast Cancer Patients,” (2000), Clin. Cancer Res. 6: 3823-3826.
Pfleiderer et al. “Detection of Tumour Cells in Peripheral Blood and Bone Marrow from Ewing Tumour Patients by RT-PCR,” (1995), Int. J. Cancer. 64: 135-139.
Hla et al. “Human cyclooxygenase-2 cDNA,” (1992), Proc. Natl. Acad. Sci. U. S. A. 89: 7384-7388.
Subbarayan et al. “Differential Expression of Cyclooxygenase-2 and Its Regulation by Tumor Necrosis Factor-a in Normal and Malignant Prostate Cells,” (2001), Cancer Res. 61: 2720-2726.
Yoshimura et al. “Expression of Cycloocygenase-2 in Prostate,” (2000), Cancer 89(3): 589-596.
Agoff et al. “The Role of Cyclooxygenase 2 in Ulcerative Colitis-Associated Neoplasia,” (2000), American Journal of Pathology 157(3): 737-745.
Lim et al. “Nuclear Factor-kB Regulates Cyclooxygenase-2 Expression and Cell Proliferation in Human Gastric Cancer Cells,” (2001), Laboratory Investigation 81(3): 349-360.
Sales et al. “Cyclooxygenase-2 Expression and Prostaglandin E2 Synthesis Are Up-Regulated in Carcinomas of the Cervix: A Possible Autocrine/Paracrine Regulation of Neoplastic Cell Function via EP2/EP4 Receptors,” (2001), Journal of Clinical Endocrinology & Metabolism 86(5): 2243-2249.
Souza et al. “Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells,” (2000), Cancer Research 60: 5767-5772.
Zhou et al. “Circulating RNA as a novel tumor marker: An in vitro study of the origins and characteristics of extracellular RNA,” (2008), Cancer Letters 259: 50-60.
Theodor et al. “Diagnostic Value of K-ras Mutations in Circulating DNA from Serum,” (1999), Diges. Dis. Sci. 44: 2014-2019.
Kobayashi et al. “Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells,” (2000), J. Lab. Clin. Med. 135: 199-209.
Kubo et al. “Point Mutations of the Topoisomerase IIa Gene in Patients with Small Cell Lung Cancer Treated with Etoposide,” (1996), Cancer Res. 56: 1232-1236.
Mermin et al., (Detection of Human Immunodeficiency Virus DNA and RNA in Semen by the Polymerase Chain Reaction, Journal of Infectious Diseases 164:769-72 (1991).
Laseeb et al., “Semen Characteristics in HIV-1 positive men and the effect of semen washing,” Genitourin Med. 73:303-305 (1997).
Horlick Kenneth R.
McDonnell & Boehnen Hulbert & Berghoff
OncoMEDx, Inc.
Thomas David C
LandOfFree
Methods for evaluating drug-resistance gene expression in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for evaluating drug-resistance gene expression in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for evaluating drug-resistance gene expression in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4205420